股票上市地点：上海证券交易所 股票简称：山大地纬 股票代码：688579 信息披露义务人一： 名称：山东高速集团有限公司 通讯地址：山东省济南市历下区龙奥北路8号 信息披露义务人二： 登录新浪财经APP 搜索【信披】查看更多考评等级 上市公司名称：山大地纬软件股份有限公司 名称：山东山大资本运营有限公司 通讯地址：山东省济南市历城区山大南路29号鲁能科技大厦A座506 权益变动性质：持股数量不变，因信息披露义务人签订《一致行动人协议》合并计算持股数量而履行的 信息披露义务。 签署日期：2026年2月 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司收购管理 办法》（以下简称"《收购管理办法》"）、《公开发行证券的公司信息披露内容与格式准则第15号—权 益变动报告书》（以下简称"准则15号"）、《公开发行证券的公司信息披露内容与格式准则第16号—— 上市公司收购报告书》（以下简称"准则16号"）及相关的法律法规编写本报告书。 二、依据《证券法》《收购办法》、准则15号、准则16号的规定，本报告书已全面披露了信息披露义务 人在山大地纬软件股份有限公司中拥有权 ...

瑞财经 刘治颖 2月2日，深圳核心医疗科技股份有限公司（以下简称：核心医疗）披露审核问询函之回 复，拟科创板上市，保荐机构为华泰联合证券，保荐代表人为任雅静、肖斯峻，会计师事务所为安永华 明。 招股书显示，核心医疗是一家专注于人工心脏领域创新型医疗器械研发、生产和销售的国家高新技术企 业。公司现已全面布局植入式和介入式人工心脏产品，致力于解决全国超千万心衰患者的迫切临床需 求。 回复文件披露，核心有限设立时的注册资本为1000万元，股东余顺理所持股权均系代余顺周持有，该等 出资额均未实缴。核心有限设立时注册资本1000万元对应股权（以下简称"目标股权"）的演变情况如 下： | 府号 | 股东姓名/ 名称 | 实缴出资完成 时间 | 实缴金 额(万 | 合计实缴金额 (万元) | 实缴方式 | 资金来源 | | --- | --- | --- | --- | --- | --- | --- | | 3 | 余顺周 | 2019年5月 | 元) 100.00 | | 货币 | 自有资金 | | 4 | 余顺周 | 2019年5月 | 250.00 | | 货币 | 自有资金 | | ર | 余顺周 | 2019年 ...

Core Viewpoint - Longchen Technology Co., Ltd. is preparing for an initial public offering on the Beijing Stock Exchange, with a focus on its BOPP film materials business, and has responded to the second round of inquiry letters from the exchange [2]. Company Overview - Longchen Technology was established in 2003 and specializes in the research, production, and sales of BOPP film materials, which are categorized into base films and metallized films. The company has been listed on the New Third Board since 2015 [2]. Shareholding Structure - As of the signing date of the prospectus, Lin Meiyun directly holds 53.66 million shares, representing 52.61% of the company, and controls an additional 1.47% through her role as the executive partner of Zeming Xincheng, totaling 54.08% ownership. The fourth largest shareholder, Lin Weiliang, holds 3.48% and is Lin Meiyun's brother [2][3]. Inquiry from the Beijing Stock Exchange - The Beijing Stock Exchange has requested Longchen Technology to clarify the relationship between Lin Weiliang and Lin Meiyun, including whether Lin Weiliang is considered a concerted actor with Lin Meiyun, and to provide details on shareholding lock-up and reduction arrangements post-listing [2]. Lin Weiliang's Background - Lin Weiliang has been involved with the company since 2010, acquiring shares through stock transfers. He previously served as a director and is currently the assistant to the chairman, focusing on daily operations and decision implementation [3][4]. Clarification on Concerted Action - Longchen Technology does not recognize Lin Weiliang as a concerted actor with Lin Meiyun due to several reasons, including the absence of a concerted action agreement, independent attendance at board meetings, and a lack of involvement in major decision-making processes [4][5]. Commitment Letters - Both Lin Weiliang and Lin Meiyun have issued commitment letters stating that there is no concerted action relationship, and Lin Weiliang has also provided a commitment regarding share lock-up and reduction [4]. Management Background - Lin Meiyun, born in August 1969, has a background in business management and has held various executive positions in multiple companies since 1998, including her current roles at Longchen Technology and other related firms [5].

Core Viewpoint - Dongtong Tui (300379) has completed its last trading day on January 21, 2026, and announced its delisting. However, during the 15-day delisting adjustment period, there has been significant capital accumulation, raising questions about potential control disputes and coordinated actions among investors [1]. Group 1: Trading Activity - Guotai Haitong Securities Fuyang Xihu Avenue branch has been aggressively buying Dongtong Tui shares for 14 consecutive trading days, accumulating a total purchase amount of 86.12 million yuan, with only 875 yuan in sales [1][3]. - The estimated shareholding from this branch reached 51.28 million shares, accounting for 9.19% of the total share capital, surpassing the 5% disclosure threshold and the controlling shareholder Huang Yongjun's 7.66% stake [1][3]. - The buying activity has been characterized by a steady increase in daily purchase amounts, peaking at 9.49 million yuan on January 19, 2026 [3]. Group 2: Institutional Participation - Multiple institutional seats have appeared on the trading leaderboard, with significant net purchases, including 7.89 million yuan on January 21, 2026, and 1.49 million yuan on January 20, 2026 [4]. - The total net purchase amount from the leaderboard during the 15-day period reached 123 million yuan, indicating a fierce competition for shares [4]. Group 3: Potential Control Disputes - The capital accumulation around Dongtong Tui resembles previous cases, such as Guangyi Tui, where coordinated buying led to significant shareholding increases without proper disclosure [5]. - There are indications that the buying may involve multiple accounts to circumvent regulatory limits on daily purchases, suggesting potential collusion among investors [6][7]. - The weak control structure of Dongtong Tui, with the controlling shareholder's stake being only 7.66%, presents an opportunity for capital intervention and control disputes [9]. Group 4: Financial Health - Despite its delisting due to major violations, Dongtong Tui's financial situation appears relatively stable, with total assets of 3.435 billion yuan and liabilities of only 381 million yuan as of September 30, 2025 [9]. - The company reported a revenue of 419 million yuan in the first three quarters of 2025, with a gross margin of 72.86%, although it still recorded a net loss of 83.99 million yuan [9].

证券代码：688399 证券简称：硕世生物 公告编号：2025-047 江苏硕世生物科技股份有限公司 关于实际控制人续签一致行动协议的公告 房永生、梁锡林通过绍兴闰康生物医药股权投资合伙企业(有限合伙)共同控制公司27.53%股权，房永 生、梁锡林通过泰州硕源企业管理咨询合伙企业（有限合伙）、泰州硕康企业管理咨询合伙企业（有限 合伙）共同控制公司3.81%股份，房永生通过泰州硕鑫企业管理咨询合伙企业（有限合伙）、泰州硕科 企业管理咨询合伙企业（有限合伙）、泰州硕和企业管理咨询合伙企业（有限合伙）控制公司0.90%股 份，房永生先生为公司名誉董事长、董事、董事会战略委员会主任委员，王国强先生持有公司8.73%股 权且担任公司的董事长兼总经理，长期管理公司的生产经营。 上述三人于公司首次公开发行股票并上市前签署了《一致行动协议》，并分别于2022年12月5日、2023 年12月5日、2024年12月5日续签了《一致行动协议》。为促进公司持续稳健发展，基于共同理念，经充 分沟通协商，房永生、梁锡林和王国强于2025年12月5日续签了《一致行动协议》。 二、本次续签《一致行动协议》的主要内容 甲方：房永生 乙方：梁锡 ...

Core Viewpoint - Huaxia Eye Hospital (301267.SZ) has signed a supplementary agreement to extend the validity of the existing concerted action agreement by three years, until November 7, 2028, to maintain the stability of its corporate governance structure and improve decision-making efficiency [1] Shareholding Structure - Mr. Su Qingcan, the chairman and general manager of the company, directly holds 255,405,989 shares, accounting for 30.41% of the total shares [1] - Through holding 84% of Huaxia Medical Investment (Xiamen) Co., Ltd., the largest shareholder, Mr. Su controls an additional 214,841,769 shares, representing 25.58% of the total shares [1] - In total, Mr. Su holds 470,247,758 shares, which is 55.98% of the total shares, either directly or indirectly [1] Concerted Action Agreement - Ms. Su Shihua is recognized as a concerted actor with Mr. Su Qingcan, and together they hold a total of 529,194,600 shares, which constitutes 63.00% of the total shares [1]

Group 1 - The actual controllers of Zhongyuan Co., Ltd. signed a voting rights entrustment agreement, transferring a total of 100.5 million shares' voting rights to Zhu Shuangquan and Zhu Shunquan, resulting in them holding 20.71% of the voting rights after the agreement takes effect [1] - Zhu Shuangquan, Zhu Shunquan, and Zhu Mengqian signed a concerted action agreement, collectively holding 25.63% of the voting rights, leading to a change in the actual controllers of the company [1] - The company plans to issue up to 61.35 million shares, not exceeding 30% of the total share capital before the issuance, with a total fundraising amount not exceeding 500 million RMB [2] Group 2 - The company's stock will resume trading on November 3, 2025, following an application to the Shenzhen Stock Exchange [3]

Core Viewpoint - The report details the equity change of Shouhua Gas Technology (Shanghai) Co., Ltd., indicating that Shanghai Houde Miaojing Business Consulting Co., Ltd. has increased its shareholding, aiming to gain control over the company and enhance its operational efficiency and governance structure [1][14]. Group 1: Equity Change Details - Shanghai Houde plans to acquire 27,216,000 shares, representing 10.02% of the total share capital of Shouhua Gas, from Ganzhou Haide Investment Partnership [19]. - The total payment for the shares is set at RMB 330.6744 million, with the first payment of RMB 100 million already made [20][23]. - After the transaction, the combined shareholding of Shanghai Houde, Shanxi Huijing, and Liu Jinli will amount to 35,165,308 shares, or 12.94% of the total share capital [18]. Group 2: Stakeholder Information - Liu Qingli is identified as the actual controller of both Shanghai Houde and Shanxi Huijing, establishing a unified action relationship among the stakeholders [14][17]. - Shanxi Huijing holds 100% of its shares under the control of China Panorama Energy Ltd., with Liu Qingli as the actual controller [9][10]. - Liu Jinli directly holds 17,183,968 shares, accounting for 6.32% of the total share capital [17]. Group 3: Future Plans and Governance - The purpose of the equity change is to recognize the value and development prospects of Shouhua Gas, with plans to improve operational efficiency and governance [14]. - The stakeholders commit to not transferring the acquired shares within 18 months post-acquisition and may consider further acquisitions based on business needs [14][23]. - No immediate plans for significant changes to the main business operations of Shouhua Gas have been outlined for the next 12 months [23].

Core Viewpoint - The report details the equity change of Daheng New Era Technology Co., Ltd., highlighting the signing of a concerted action agreement between Li Rongrong and Zhou Zhengchang, resulting in an increase in their combined shareholding to 9.26% of the company's total equity [1][5][7]. Group 1: Equity Change Details - The equity change is due to the signing of a concerted action agreement on August 16, 2025, which allows Li Rongrong and Zhou Zhengchang to act together in shareholder meetings and board decisions [6][9]. - Prior to the agreement, Li Rongrong held 27,460,000 shares (6.29% of total equity) and Zhou Zhengchang held 13,000,000 shares (2.98% of total equity) [7][8]. - After the agreement, their combined shareholding increased to 40,460,000 shares, representing 9.26% of the total equity [7][8]. Group 2: Purpose and Future Plans - The purpose of the equity change is to protect the mutual interests of the parties involved and to ensure a unified decision-making process in the company's governance [6][9]. - There are currently no plans to increase their shareholding further within the next 12 months [7][15]. - The parties have no intentions to change the company's main business or make significant adjustments to its operations in the near future [15][17]. Group 3: Financial and Legal Compliance - The funds used for acquiring shares were sourced from personal or self-raised funds, with no involvement from the company or its affiliates [13][14]. - The report confirms that the parties have complied with all relevant legal and regulatory requirements, ensuring the accuracy and completeness of the disclosures made [20][21].

Core Viewpoint - The Anhui Securities Regulatory Commission has ordered Oriental Materials' major shareholders to rectify their actions due to discrepancies in information disclosure, prohibiting them from exercising voting rights on their shares until corrections are made [1][5]. Group 1: Shareholder Actions - In May, Jiangsu Teliang New Materials Technology Co., Ltd. acquired a 5.96% stake in Oriental Materials through auction and stated no plans for further share changes within the next 12 months [2]. - Hongsheng Dingrong Investment Management Partnership, established on May 29, participated in a judicial auction for 3.49% of Oriental Materials' shares, increasing its holdings to 7.0241 million shares by June 30 [3][4]. Group 2: Regulatory Findings - The Anhui Securities Regulatory Commission found that Teliang and Hongsheng Dingrong violated regulations by not disclosing their status as concerted actors in their May 30 report [5]. - The commission has mandated that both companies suspend acquisition activities and submit a written rectification report within 30 days of receiving the regulatory decision [5]. Group 3: Legal and Compliance Considerations - The determination of when a concerted action relationship is established can vary, with two potential methods: factual establishment or formal disclosure [7]. - Legal experts suggest that if decisions and communications occurred before the May 30 report, the concerted action could be recognized from that date rather than the later announcement on June 6 [8].